Search
Bosentan
go.drugbank.com/drugs/DB00559ApprovedInvestigationalBosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. … Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.
Mixtures: OCUBRAX® SUSPENSION OFTALMICA, OCUBRAX® SUSPENSION OFTALMICACategories: Genito Urinary System and Sex Hormones, Cytochrome P-450 SubstratesTerazosin
go.drugbank.com/drugs/DB01162ApprovedInvestigationalTerazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label][A176831]. … Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate[A176837].
Synonyms: 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazineMixtures: Hytrin-7 Tabs 1mg-7 Tabs 2mg-14 Tabs 5mg, Hytrin-7 Tabs 1mg-7 Tabs 2mg-14 Tabs 5mgSebelipase alfa
go.drugbank.com/drugs/DB11563ApprovedInvestigational[L39337] Sebelipase alfa is a recombinant form LAL approved for the treatment of LAL deficiency. … It was first approved by both the FDA and EMA in 2015 and is marketed under the brand name Kanuma (Alexion Pharmaceuticals).[L39337,L39342]
Products: KANUMA® 2 MG/ML CONCENTRADO PARA SOLUCION PARA INFUSION.Gadoteridol
go.drugbank.com/drugs/DB00597ApprovedInvestigational[A263076,A263081,L49871] It was 1 of the 3 macrocyclic gadolinium-based contrast agents (GBCAs) that was mandated by the EMA to replace linear gadolinium-based contrast agents due to concerns about retained … [A263076] Initially approved by the FDA in 1992, gadoteridol received additional approval in 2020 for use in pediatric patients less than 2 years old.[L49876]
Categories: Compounds used in a research, industrial, or household settingSynonyms: gadolinium 2,2',2''-[10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetateNivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigationalNivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). … [A35203] It was developed by Bristol Myers Squibb.[L12129] Nivolumab was granted FDA approval on 22 December 2014.
Mixtures: OPDUALAG® SOLUCION INYECTABLECategories: Immunoglobulin G, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitorsThiotepa
go.drugbank.com/drugs/DB04572ApprovedInvestigationalN,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. … It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer.
Synonyms: Tris(Aziridin-1-yl)-sulfanylideneλ5phosphane, N,N′,N′′-tri-1,2-ethanediyl-Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InhibitorsCefalotin
go.drugbank.com/drugs/DB00456ApprovedVet approvedWithdrawnCefalotin is a cephalosporin antibiotic.
Synonyms: 3-Acetoxymethyl-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid, 7-(Thiophene-2-acetamido)cephalosporinCategories: Heterocyclic Compounds, 2-RingRamelteon
go.drugbank.com/drugs/DB00980ApprovedInvestigationalRamelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: RAMELDA 8 MG FILM KAPLI TABLET,30 ADET, ROZEREST 8 MG FİLM KAPLI TABLET, 10 ADETPhenylephrine
go.drugbank.com/drugs/DB00388ApprovedInvestigationalPhenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil,[L9413] and induce local vasoconstriction.
Mixtures: DAYCOLD-HOT 500/10/15/100 MG SAŞE ,20 SAŞE, DEFLU 300 MG/5 MG/2 MG TABLET, 20 ADETCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersBaricitinib
go.drugbank.com/drugs/DB11817ApprovedInvestigational[L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018. … [A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: UNAMİTY 4 MG FİLM KAPLI TABLET, 7 ADET, UNAMİTY 2 MG FİLM KAPLI TABLET, 7 ADET